REAL-LIFE USE OF LETERMOVIR IN PAEDIATRIC AND YOUNG ADULT PATIENTS. A RETROSPECTIVE STUDY ON BEHALF OF SPANISH GROUP FOR HAEMATOPOIETIC TRANSPLANTATION AND CELLULAR THERAPY (ESPID 2026) - Mar 5, 2026 - Abstract #OP-062; Pres time: Jun 5, 2026; 10:50 AM - 11:00 AM; Location: Sala Italia; "Conclusions/Learning Points In this large real-world multicentre cohort, letermovir demonstrated a favourable safety profile and was associated with low rates of CMV disease in paediatric HSCT recipients. These findings support the use of letermovir as an effective and well-tolerated CMV prophylactic strategy in this population."
Retrospective data • Cytomegalovirus Infection • Infectious Disease
|
|
Cristina Rivera Pérez; Silvia Simó Nebot; Andrea Urtasun-Erburu; Yasmina Mozo del Castillo; Laura Alonso García; Marina García Morín; Ivan Lopez Torija; Jaime Verdú Amorós; Maria Trabazo del Castillo; Estela Blanquiz Ibero; David Bueno; Glòria Miguel Llordés; Luisa Sisinni; Julià Gotzens; Núria Mas Malagarriga; Montserrat Rovira Tarrats; Júlia Marsal Ricoma
|